KTH Royal Institute of Technology, Department of Biomedical Engineering and Health Systems, Stockholm, Sweden.
Henry Ford Hospital, Detroit, Michigan.
J Card Fail. 2024 Apr;30(4):596-609. doi: 10.1016/j.cardfail.2024.01.011. Epub 2024 Feb 29.
The field of durable mechanical circulatory support (MCS) has undergone an incredible evolution over the past few decades, resulting in significant improvements in longevity and quality of life for patients with advanced heart failure. Despite these successes, substantial opportunities for further improvements remain, including in pump design and ancillary technology, perioperative and postoperative management, and the overall patient experience. Ideally, durable MCS devices would be fully implantable, automatically controlled, and minimize the need for anticoagulation. Reliable and long-term total artificial hearts for biventricular support would be available; and surgical, perioperative, and postoperative management would be informed by the individual patient phenotype along with computational simulations. In this review, we summarize emerging technological innovations in these areas, focusing primarily on innovations in late preclinical or early clinical phases of study. We highlight important considerations that the MCS community of clinicians, engineers, industry partners, and venture capital investors should consider to sustain the evolution of the field.
在过去的几十年中,耐用型机械循环支持(MCS)领域发生了令人难以置信的演变,为晚期心力衰竭患者的寿命和生活质量带来了显著改善。尽管取得了这些成功,但仍有很大的改进空间,包括泵设计和辅助技术、围手术期和术后管理以及整体患者体验。理想情况下,耐用型 MCS 设备应该完全可植入、自动控制,并尽量减少抗凝的需求。可靠且长期的双心室支持的全人工心脏将可用;并且手术、围手术期和术后管理将由个体患者表型以及计算模拟来指导。在这篇综述中,我们总结了这些领域的新兴技术创新,主要关注研究的后期临床前或早期临床阶段的创新。我们强调了 MCS 临床医生、工程师、行业合作伙伴和风险投资家群体应该考虑的重要因素,以维持该领域的发展。